Cambridge Healthtech Institute’s 5th Annual
Neoantigen Targeted Therapies and Personalized Cancer Vaccines
Personalized Cancer Immunotherapy in the Genomic Era
August 13-14, 2020
Fueled with advances in genomic technologies, personalized oncology promises to innovate cancer therapy and target previously undruggable space. Developments in NGS technology enabled systematic analysis of patient-specific mutanome and opened the door to developing personalized cancer vaccines and other therapies targeting neoantigens. Cambridge Healthtech Institute’s Fifth Annual Neoantigen Targeted Therapies and Personalized Cancer Vaccines meeting brings together thought leaders from pharmaceutical and biotech companies, leading academic teams and clinical immuno-oncologists to share research and case studies in implementing patient-centric approaches to using the immune system to beat cancer, including utilizing NGS to identify tumor-specific neoantigens, using in silico tools to predict immunogenic neoepitopes, and targeting them with personalized vaccines, novel antibodies or combination therapies.
NEOANTIGEN SELECTION AND THERAPEUTIC TARGETING
Clinical Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes
Philip Arlen, MD, President & CEO, Precision Biologics
Talk Title to be Announced
Stephen Schoenberger, PhD, Co-Director, San Diego Center for Precision Immunotherapy; Professor, La Jolla Institute for Allergy and Immunology
Talk Title to be Announced
Karin Jooss, PhD, CSO, Gritstone Oncology
True Tumor-Rejection Mediating Neo-Epitopes – Embarrassment of Riches
Pramod Srivastava, MD, PhD, Director, Carole and Ray Neag Comprehensive Cancer Center; Professor, Immunology and Medicine, University of Connecticut School of Medicine
Updated Approaches for Neoantigen Vaccination for Oncology
David A. Reardon, MD, Professor, Medicine, Harvard Medical School; Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute
Bringing Personalized Cancer Vaccines to the Patients: Update on Clinical Data, Challenges and Learnings from the VB N-01 Clinical Study
Agnete Fredriksen, PhD, CSO, Vaccibody
Personalized Treatments for Cancer – At the Intersection of Precision Medicine and Immunotherapy
Niranjan Y. Sardesai, PhD, Co-Founder, President & CEO, Geneos Therapeutics
Th17-Inducing Vaccines for the Treatment of Cancer
Keith Knutson, PhD, Professor, Immunology; Director, Immunology & Immunotherapy Program, Mayo Clinic
Can Vaccination Overcome Immune Ignorance and Segregation within the Tumor Microenvironment?
Robert Pierce, MD, Scientific Director, Immunopathology Core, Fred Hutchinson Cancer Research Center
VIROTHERAPY AND VACCINATION: COMBINATION APPROACHES
Oncolytic Immunotherapy Combinations in Pancreatic Cancer
Christos Fountzilas, MD, Assistant Professor, Oncology, Roswell Park Comprehensive Cancer Center
Use of Enveloped Virus-Like Particles (eVLPs) in Immuno-Oncology
David Anderson, PhD, CSO, Research & Development, VBI Vaccines, Inc.
Effective Vaccination with Adenoviral Vectors Encoding Multiple Neoantigens Drives Clonal Expansion of T Cells Infiltrating the Tumors
Elisa Scarselli, MD, CSO, Nouscom AG
* The program is subject to change without notice, due to unforeseen reason.